Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Owlet, Inc.NYSE: OWLT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $185K rose 25.0% year over year, ahead of the -41.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 12.1% from the prior quarter. Over 3 fiscal years it compounded at -39.6% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 1.2 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +25.0% holds above the trailing-twelve-month pace of -41.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 590K USD
- Year-over-year change
- -57.3%
- 4-year CAGR
- -15.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 590K | -57.3% |
| FY2024 | 2024-12-31 | 1.38M | -37.5% |
| FY2023 | 2023-12-31 | 2.21M | -17.2% |
| FY2022 | 2022-12-31 | 2.67M | +135.7% |
| FY2021 | 2021-12-31 | 1.13M | — |
Depreciation & Amortization vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 depreciation & amortization of $627K is the 9th highest of the 10 companies compared; the peer median is $1.69M.
- Its year-over-year change of -41.1% is the 9th highest of 10, against a peer median of -2.3%.
- Depreciation & amortization amounts to 0.6% of revenue for OWLT, versus a peer median of 13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.63M | -26.5% | -26.6% | 4.8% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $4.48M | -11.7% | +24.0% | 13.9% | |
| LTM Mar 2026 | $3.11M | -4.9% | +4.7% | 9.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +8.7% | +29.0% | 91.1% |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M | -2.3% | +2.2% | — |
| LTM Mar 2026 | $1.03M | +94.7% | +56.5% | 196.6% | |
| LTM Mar 2026 | $873K | -1.6% | -23.3% | 17.0% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Mar 2026 | $248K | -57.2% | -46.1% | — | |
| Peer median (excluding OWLT) | $1.69M | -2.3% | +4.7% | 13.9% | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.84M | 69.2M | 54.01M | 78.06M | 105.71M |
| Cost of Revenue | 40.78M | 45.89M | 31.42M | 38.75M | 52.18M |
| Gross Profit | 35.06M | 23.31M | 22.59M | 39.31M | 53.53M |
| Gross Margin | 46.2% | 33.7% | 41.8% | 50.4% | 50.6% |
| Research & Development | 21.43M | 27.9M | 10.35M | 9.8M | 14.08M |
| Selling, General & Admin | 69.42M | 80.04M | 40.87M | 49.73M | 47.72M |
| Operating Expenses | 90.85M | 107.93M | 51.22M | 59.53M | 61.79M |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| EBITDA | (42.71M) | (75.53M) | (27.49M) | (9.47M) | (35.64M) |
| EBITDA Margin | -56.3% | -109.1% | -50.9% | -12.1% | -33.7% |
| Operating Income | (55.79M) | (84.62M) | (28.63M) | (20.22M) | (8.26M) |
| Operating Margin | -73.6% | -122.3% | -53.0% | -25.9% | -7.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 27.83M | 1.1M | 3.19M | 1.63M | 3.42M |
| Other Income / Expenses | (15.88M) | 5.31M | (4.26M) | 7.74M | (31.39M) |
| Income Before Tax | (71.67M) | (79.31M) | (32.89M) | (12.48M) | (39.65M) |
| Pre-Tax Margin | -94.5% | -114.6% | -60.9% | -16.0% | -37.5% |
| Income Tax Expense | 31K | 29K | 10K | 54K | 28K |
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (39.68M) |
| Net Margin | -94.5% | -114.6% | -60.9% | -16.1% | -37.5% |
| EPS (Basic) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| EPS (Diluted) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| Weighted Avg Shares | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
| Weighted Avg Shares (Diluted) | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.